FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2186129552> ?p ?o ?g. }

• W2186129552 endingPage "192" @default.
• W2186129552 startingPage "187" @default.
• W2186129552 abstract "It has been proposed that the activity of a second-line treatment regimen can be documented by showing that the time to progression (TTP) following second-line therapy is longer than the TTP following first-line therapy in the same patients.The ratio of TTP during first and second-line therapy, identified as the growth modulation index (GMI), was determined in 34 patients with advanced colorectal cancer. First-line chemotherapy consisted of one of several schedules of leucovorin (LV)-modulated 5-fluorouracil (5-FU) or raltitrexed. Second-line therapy consisted of the combination of LV-modulated 5-FU and oxaliplatin (1-OHP). Patients were switched to second-line therapy upon evidence of progressive disease following first-line therapy.Median TTP following first-line therapy was 13 weeks (95% confidence interval (CI): 7.6-18.7), while median TTP following second-line therapy was 31 weeks (95% CI: 21.3-41.0). Sixteen patients (47%; 95% CI: 35%-59%), showed a GMI > or = 1.33, while the remaining 18 patients (53%; 95% CI: 40%-66%) had a GMI < 1.33. Log-rank analysis of the Kaplan-Meier curves of TTP following first- versus second-line therapy demonstrated a statistically significant difference in favour of second-line therapy (P = 0.0081).This study demonstrates the utility of the GMI as a tool for assessing the activity of novel second-line therapeutic programs." @default.
• W2186129552 created "2016-06-24" @default.
• W2186129552 creator A5011160865 @default.
• W2186129552 creator A5014868069 @default.
• W2186129552 creator A5015129746 @default.
• W2186129552 creator A5021831940 @default.
• W2186129552 creator A5022686973 @default.
• W2186129552 creator A5024148760 @default.
• W2186129552 creator A5027172953 @default.
• W2186129552 creator A5039426761 @default.
• W2186129552 creator A5045621431 @default.
• W2186129552 creator A5065872850 @default.
• W2186129552 creator A5084410786 @default.
• W2186129552 date "2001-02-01" @default.
• W2186129552 modified "2023-09-28" @default.
• W2186129552 title "Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma" @default.
• W2186129552 cites W1863898801 @default.
• W2186129552 cites W1899541887 @default.
• W2186129552 cites W1912318374 @default.
• W2186129552 cites W1941365207 @default.
• W2186129552 cites W1946289873 @default.
• W2186129552 cites W1955547739 @default.
• W2186129552 cites W1969321574 @default.
• W2186129552 cites W2001797895 @default.
• W2186129552 cites W2006824814 @default.
• W2186129552 cites W2017069590 @default.
• W2186129552 cites W2028547579 @default.
• W2186129552 cites W2032146688 @default.
• W2186129552 cites W2032553799 @default.
• W2186129552 cites W2033465919 @default.
• W2186129552 cites W2059916220 @default.
• W2186129552 cites W2064353452 @default.
• W2186129552 cites W2067111148 @default.
• W2186129552 cites W2070804934 @default.
• W2186129552 cites W2085643819 @default.
• W2186129552 cites W2096122707 @default.
• W2186129552 cites W2105427184 @default.
• W2186129552 cites W2121368761 @default.
• W2186129552 cites W2122731269 @default.
• W2186129552 cites W2128941960 @default.
• W2186129552 cites W2167805334 @default.
• W2186129552 cites W2240214496 @default.
• W2186129552 cites W2253177453 @default.
• W2186129552 cites W2259194869 @default.
• W2186129552 cites W2396646859 @default.
• W2186129552 cites W2422699435 @default.
• W2186129552 cites W2602544133 @default.
• W2186129552 cites W4238668552 @default.
• W2186129552 doi "https://doi.org/10.1023/a:1008354909478" @default.
• W2186129552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11300322" @default.
• W2186129552 hasPublicationYear "2001" @default.
• W2186129552 type Work @default.
• W2186129552 sameAs 2186129552 @default.
• W2186129552 citedByCount "17" @default.
• W2186129552 countsByYear W21861295522013 @default.
• W2186129552 countsByYear W21861295522016 @default.
• W2186129552 countsByYear W21861295522018 @default.
• W2186129552 countsByYear W21861295522020 @default.
• W2186129552 countsByYear W21861295522021 @default.
• W2186129552 countsByYear W21861295522022 @default.
• W2186129552 crossrefType "journal-article" @default.
• W2186129552 hasAuthorship W2186129552A5011160865 @default.
• W2186129552 hasAuthorship W2186129552A5014868069 @default.
• W2186129552 hasAuthorship W2186129552A5015129746 @default.
• W2186129552 hasAuthorship W2186129552A5021831940 @default.
• W2186129552 hasAuthorship W2186129552A5022686973 @default.
• W2186129552 hasAuthorship W2186129552A5024148760 @default.
• W2186129552 hasAuthorship W2186129552A5027172953 @default.
• W2186129552 hasAuthorship W2186129552A5039426761 @default.
• W2186129552 hasAuthorship W2186129552A5045621431 @default.
• W2186129552 hasAuthorship W2186129552A5065872850 @default.
• W2186129552 hasAuthorship W2186129552A5084410786 @default.
• W2186129552 hasBestOaLocation W21861295521 @default.
• W2186129552 hasConcept C121608353 @default.
• W2186129552 hasConcept C126322002 @default.
• W2186129552 hasConcept C143998085 @default.
• W2186129552 hasConcept C2776694085 @default.
• W2186129552 hasConcept C2779268555 @default.
• W2186129552 hasConcept C2780259306 @default.
• W2186129552 hasConcept C2780456651 @default.
• W2186129552 hasConcept C2780775027 @default.
• W2186129552 hasConcept C2780962732 @default.
• W2186129552 hasConcept C2781413609 @default.
• W2186129552 hasConcept C2909905744 @default.
• W2186129552 hasConcept C44249647 @default.
• W2186129552 hasConcept C526805850 @default.
• W2186129552 hasConcept C71924100 @default.
• W2186129552 hasConcept C90924648 @default.
• W2186129552 hasConceptScore W2186129552C121608353 @default.
• W2186129552 hasConceptScore W2186129552C126322002 @default.
• W2186129552 hasConceptScore W2186129552C143998085 @default.
• W2186129552 hasConceptScore W2186129552C2776694085 @default.
• W2186129552 hasConceptScore W2186129552C2779268555 @default.
• W2186129552 hasConceptScore W2186129552C2780259306 @default.
• W2186129552 hasConceptScore W2186129552C2780456651 @default.
• W2186129552 hasConceptScore W2186129552C2780775027 @default.
• W2186129552 hasConceptScore W2186129552C2780962732 @default.
• W2186129552 hasConceptScore W2186129552C2781413609 @default.

• next